Literature DB >> 8971021

Apoptosis by CD95 (Fas)-dependent and -independent mechanisms in Peyer's patch lymphocytes in murine retrovirus-induced immunodeficiency syndrome.

J Usami1, K Hiromatsu, Y Aoki, N Kobayashi, M Makino, H Yagita, Y Matsumoto, K Maeda, Y Yoshikai.   

Abstract

CD95 (Fas)/CD95 ligand (CD95 L)-mediated apoptosis is thought to be involved in the delayed progression of murine AIDS (MAIDS) induced by LP-BM5 murine leukemia virus (MuLV). We show evidence of apoptosis in lymphocytes of Peyer's patches (PP) at the early stage of MAIDS. Both T and B cells in PP expressed CD95 at the early stage of MAIDS and decreased in number thereafter. The decrease in T cells was not evident in CD95-mutated lpr mice with MAIDS, suggesting that CD95/CD95 L interaction is involved in the apoptosis of T cells in PP during the course of MAIDS. On the other hand, the number of B cells was also decreased in PP of lpr mice with MAIDS. The proliferative ability of B cells in PP of MAIDS mice in response to immunoglobulin M cross-linking or lipopolysaccharide was severely impaired, while the B cells normally proliferated in response to anti-CD40 monoclonal antibody. These findings imply that aberrantly activated B cells in PP undergo apoptosis independently of the CD95/CD95 L system during the course of infection with MAIDS virus.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8971021      PMCID: PMC190989     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  High expression of APO-1 (CD95) on T lymphocytes from human immunodeficiency virus-1-infected children.

Authors:  K M Debatin; A Fahrig-Faissner; S Enenkel-Stoodt; W Kreuz; A Benner; P H Krammer
Journal:  Blood       Date:  1994-05-15       Impact factor: 22.113

2.  Role of alpha 4-integrins in lymphocyte homing to mucosal tissues in vivo.

Authors:  A Hamann; D P Andrew; D Jablonski-Westrich; B Holzmann; E C Butcher
Journal:  J Immunol       Date:  1994-04-01       Impact factor: 5.422

3.  Identification of a murine Peyer's patch--specific lymphocyte homing receptor as an integrin molecule with an alpha chain homologous to human VLA-4 alpha.

Authors:  B Holzmann; B W McIntyre; I L Weissman
Journal:  Cell       Date:  1989-01-13       Impact factor: 41.582

4.  Characteristics of B cell proliferation and activation in murine AIDS.

Authors:  D M Klinman; H C Morse
Journal:  J Immunol       Date:  1989-02-15       Impact factor: 5.422

Review 5.  Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response.

Authors:  J Mestecky; J R McGhee
Journal:  Adv Immunol       Date:  1987       Impact factor: 3.543

6.  CD4+ T cells are required for development of a murine retrovirus-induced immunodeficiency syndrome (MAIDS).

Authors:  R A Yetter; R M Buller; J S Lee; K L Elkins; D E Mosier; T N Fredrickson; H C Morse
Journal:  J Exp Med       Date:  1988-08-01       Impact factor: 14.307

7.  Functional T lymphocytes are required for a murine retrovirus-induced immunodeficiency disease (MAIDS).

Authors:  D E Mosier; R A Yetter; H C Morse
Journal:  J Exp Med       Date:  1987-06-01       Impact factor: 14.307

8.  Retroviral induction of acute lymphoproliferative disease and profound immunosuppression in adult C57BL/6 mice.

Authors:  D E Mosier; R A Yetter; H C Morse
Journal:  J Exp Med       Date:  1985-04-01       Impact factor: 14.307

9.  Isotype specificity of helper T cell clones. Peyer's patch Th cells preferentially collaborate with mature IgA B cells for IgA responses.

Authors:  H Kiyono; M D Cooper; J F Kearney; L M Mosteller; S M Michalek; W J Koopman; J R McGhee
Journal:  J Exp Med       Date:  1984-03-01       Impact factor: 14.307

10.  Mechanisms regulating IgA class-specific immunoglobulin production in murine gut-associated lymphoid tissues. I. T cells derived from Peyer's patches that switch sIgM B cells to sIgA B cells in vitro.

Authors:  H Kawanishi; L E Saltzman; W Strober
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.